[go: up one dir, main page]

WO2008031437A3 - Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'antibiotiques - Google Patents

Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'antibiotiques Download PDF

Info

Publication number
WO2008031437A3
WO2008031437A3 PCT/DK2007/050125 DK2007050125W WO2008031437A3 WO 2008031437 A3 WO2008031437 A3 WO 2008031437A3 DK 2007050125 W DK2007050125 W DK 2007050125W WO 2008031437 A3 WO2008031437 A3 WO 2008031437A3
Authority
WO
WIPO (PCT)
Prior art keywords
eczema
allergy
asthma
treatment
infants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2007/050125
Other languages
English (en)
Other versions
WO2008031437A2 (fr
Inventor
Hans Bisgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REGION HOVEDSTADEN V/GENTOFTE HOSPITAL
REGION HOVEDSTADEN V GENTOFTE
Original Assignee
REGION HOVEDSTADEN V/GENTOFTE HOSPITAL
REGION HOVEDSTADEN V GENTOFTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REGION HOVEDSTADEN V/GENTOFTE HOSPITAL, REGION HOVEDSTADEN V GENTOFTE filed Critical REGION HOVEDSTADEN V/GENTOFTE HOSPITAL
Publication of WO2008031437A2 publication Critical patent/WO2008031437A2/fr
Publication of WO2008031437A3 publication Critical patent/WO2008031437A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le traitement de l'asthme, de l'eczéma et / ou d'allergies chez des patients, en particulier le traitement d'enfants en bas âge en vue de réduire le risque d'apparition d'asthme, d'eczéma et / ou d'allergies plus tard dans la vie, par l'administration d'une quantité efficace d'un antibiotique afin de réduire ou de supprimer la croissance bactérienne pathogène dans les voies respiratoires, ce qui empêche ainsi les bactéries pathogènes de favoriser l'asthme, l'eczéma et / ou des allergies par diverses voies. Le patient est en particulier un enfant en bas âge. De plus, la présente invention concerne également le traitement des femmes enceintes afin d'éviter aux nourrissons d'être colonisés par des bactéries lors de l'accouchement.
PCT/DK2007/050125 2006-09-13 2007-09-13 Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'antibiotiques Ceased WO2008031437A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601176 2006-09-13
DKPA200601176 2006-09-13

Publications (2)

Publication Number Publication Date
WO2008031437A2 WO2008031437A2 (fr) 2008-03-20
WO2008031437A3 true WO2008031437A3 (fr) 2008-05-02

Family

ID=39092813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/050125 Ceased WO2008031437A2 (fr) 2006-09-13 2007-09-13 Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'antibiotiques

Country Status (1)

Country Link
WO (1) WO2008031437A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102670639A (zh) * 2012-06-05 2012-09-19 金小晶 阿奇霉素的新用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENN CHRISTINE STABELL ET AL: "Maternal vaginal microflora during pregnancy and the risk of asthma hospitalization and use of antiasthma medication in early childhood", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 110, no. 1, July 2002 (2002-07-01), pages 72 - 77, XP002471023, ISSN: 0091-6749 *
BLASI F ET AL: "POTENTIAL ROLE OF ANTIBIOTICS IN THE TREATMENT OF ASTHMA", FOREST PATHOLOGY, BLACKWELL WISS.- VERLAG, BERLIN, DE, vol. 3, no. 3, September 2004 (2004-09-01), pages 237 - 242, XP009064079, ISSN: 1437-4781 *
GAINOV IAIN C ET AL: "Do macrolides have a role in the long term treatment of asthma.", PEDIATRIC RESEARCH, vol. 53, no. 4 Part 2, April 2003 (2003-04-01), & ANNUAL MEETING OF THE PEDIATRIC ACADEMIC SOCIETIES; SEATTLE, WA, USA; MAY 03-06, 2003, pages 575A, XP009096680, ISSN: 0031-3998 *
LEHMANN H S ET AL: "Staphylococcal enterotoxin-B-mediated stimulation of interleukin-13 production as a potential aetiologic factor in eczema in infants.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY DEC 2004, vol. 135, no. 4, December 2004 (2004-12-01), pages 306 - 312, XP009096566, ISSN: 1018-2438 *
PENDERS J ET AL: "Clostridium difficile and E. coli colonization in early life are associated with an increased risk of allergy", EUROPEAN JOURNAL OF EPIDEMIOLOGY, vol. 21, no. Suppl. S, July 2006 (2006-07-01), & 2ND EUROPEAN CONGRESS OF EPIDEMIOLOGY; UTRECHT, NETHERLANDS; JUNE 28 JULY 01, 2006, pages 86, XP002471024, ISSN: 0393-2990 *
SNYDER R D ET AL: "Prophylactic antibiotics in asthmatic children.", ANNALS OF ALLERGY JUL 1970, vol. 28, no. 7, July 1970 (1970-07-01), pages 307 - 312, XP009096578, ISSN: 0003-4738 *

Also Published As

Publication number Publication date
WO2008031437A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008031438A3 (fr) Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'organismes non pathogènes
NZ593111A (en) Antibacterial compounds
NZ596788A (en) Use of selected lactic acid bacteria for reducing infantile colic
WO2009088549A3 (fr) Procédés d'inhibition de la virulence bactérienne et composés s'y rapportant
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
MY169058A (en) Method for stimulating the intestinal flora
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
NZ612455A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
NZ734050A (en) Compositions comprising povidone-iodine
MX2009009931A (es) Probioticos para reducir el desarrollo de alergia en lactantes nacidos por cesarea.
TNSN06420A1 (en) Methods of treatment of endobronchial infections
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
UA107095C2 (uk) Антибіотичні мікрочастинки для інгаляції
WO2010018371A3 (fr) Agent antimicrobien et son procédé de production
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
TW200510449A (en) Acylated nonadepsipeptides
UA91541C2 (ru) Бактерицидные макроциклы v, которые содержат амидные группы
WO2008071961A8 (fr) Dérivés de 2-quinolinone et de 2-quinoxalinone et leur utilisation en tant qu'agents antibactériens
SG10201809955SA (en) Method for manufacturing composition comprising local anesthetic, heparinoid, and buffer
TW200621799A (en) Acylated nonadepsipeptides II
MX2010001403A (es) Composicion topica que contiene una combinacion de mupirocina y beclometasona.
IL194353A0 (en) Lysobactin amides
MY148124A (en) Preparation of a crystalline antibiotic substance
ZA200703166B (en) Composition comprising lactic acid and lactoferrin
WO2008031437A3 (fr) Traitement de l'asthme, de l'eczéma et / ou d'allergies à l'aide d'antibiotiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801390

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801390

Country of ref document: EP

Kind code of ref document: A2